This contract expires in 166 days (Sep 30, 2026).
FIRM FIXED PRICENO SET ASIDE USED.
QIAGEN, LLC - LIASON QUANTIFERON-TB GOLD PLUSE US & CONTROL QUANTIFERON-TB GOLD PLUS.
PIID: 36C24824P1262
Signed Date: Oct 1, 2025Effective Date: Apr 16, 2024End Date: Closes in 166 days
Key Details
Description
LIASON QUANTIFERON-TB GOLD PLUSE US & CONTROL QUANTIFERON-TB GOLD PLUS.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.
Related
Agencies
Vendors